NCT04215224 Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
| NCT ID | NCT04215224 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Zhengzhou University |
| Condition | Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,500 participants |
| Start Date | 2017-01-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,500 participants in total. It began in 2017-01-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and images of HE slices in primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine hstopathology imaging based algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.
Eligibility Criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04215224 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 90 Years, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04215224 currently recruiting?
Yes, NCT04215224 is actively recruiting participants. Contact the research team at fcczhangzy1@zzu.edu.cn for enrollment information.
Where is the NCT04215224 trial being conducted?
This trial is being conducted at Zhengzhou, China.
Who is sponsoring the NCT04215224 clinical trial?
NCT04215224 is sponsored by The First Affiliated Hospital of Zhengzhou University. The trial plans to enroll 3,500 participants.